首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1290436

全球結直腸癌藥物市場 - 2023-2030年

Global Colorectal Cancer Drugs Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球結直腸癌藥物市場在2022年達到136億美元，預計到2030年將出現有利可圖的成長，達到181億美元。在2023-2030年的預測期內，全球大腸癌藥物市場預計將呈現3.7%的複合成長率。

結直腸癌藥物包括一系列治療結直腸癌的治療方案，結直腸癌會影響到結腸或直腸。這些藥物抑制腫瘤生長，防止癌細胞擴散，並改善病人的治療效果。用於治療結腸直腸癌的主要藥物類別和特定藥物包括化療、免疫療法和其他組合藥物。

此外，對牽涉到結直腸癌的特定基因突變和分子途徑的識別，促使了靶向治療的發展；研究人員正在探索結合不同藥物以提高治療效果的好處，而臨床試驗的開展允許對新藥和治療方案進行評估，這些因素預計將在預測期內推動結直腸癌藥物。

市場動態

大腸癌藥物的臨床試驗不斷增加，在預測期內推動了全球大腸癌藥物市場的成長。

2022年9月，輝瑞公司與默克公司、安諾藥業和皮埃爾法布爾公司合作，贊助了BEACON CRC研究。該研究評估了encorafenib + cetuximab ± binimetinib方案與標準護理相比，對先前接受治療的轉移性結直腸癌（mCRC）患者的有效性，這些患者俱有特定的基因突變，稱為BRAF V600E。

隨機III期BEACON研究（NCT02928224）表明，與對照組相比，encorafenib + cetuximab ± binimetinib方案改善了總生存期和客觀反應率。這一發現為該聯合療法治療BRAF V600E突變型mCRC的療效提供了證據。

ctDNA分析表明，MAPK途徑的重新激活是抑制BRAF和EGFR後的一種常見耐藥機制，無論是否有MEK抑制。 RAS-MEK訊號通路的獲得性突變在接受雙重方案（encorafenib + cetuximab）治療的患者中更常見，而接受三重方案（encorafenib + cetuximab + binimetinib）的患者中受體訊號的增強更普遍。

結直腸癌藥物的高成本阻礙了全球結直腸癌藥物市場在預測期內的成長。

根據美國疾病控制和預防中心的數據，結直腸癌的治療費用在所有類型的癌症中排名第二，佔癌症治療相關總費用的12.6%。

醫療服務佔237億美元，而處方藥為這些費用貢獻了6億美元。此外，就口服處方藥而言，發現每個病人在生命的最後一年的平均費用最大（1,400美元），其次是初始護理階段（400美元），以及持續護理階段（約200美元）。因此，由於上述因素，預計市場將在預測期內受到阻礙。

COVID-19影響分析

由於COVID-19大流行，結直腸癌藥物市場經歷了重大干擾。全球醫療系統受到影響，促使癌症篩查、診斷和治療的延誤。結直腸癌藥物的臨床試驗也受到影響，許多試驗被推遲、延遲或修改，以確保病人安全和遵守與大流行病有關的限制。

因此，新藥的開發和引進速度被放慢了。此外，大流行病的經濟影響給醫療系統和個人帶來了財政限制，可能會影響結直腸癌藥物的可負擔性和可獲得性。這些綜合因素明顯影響了結直腸癌藥物市場的動態。

俄羅斯-烏克蘭衝突分析

俄羅斯和烏克蘭之間正在進行的衝突極大地影響了烏克蘭的結直腸癌藥物的供應。在衝突之前，烏克蘭在很大程度上依賴俄羅斯進口藥品，包括癌症藥物。然而，在衝突和隨後的貿易限制之後，獲得這些藥物的機會變得有限，促使關鍵藥物的短缺，包括用於治療結腸直腸癌的藥物。

由於這種短缺，病人無法獲得基本藥物，促使治療延誤，並使用替代的、不太有效的藥物。此外，進口藥物的成本增加，使患者和醫療系統更難負擔。烏克蘭貨幣的貶值進一步加劇了這種情況，使從其他國家購買藥品變得更加困難。

俄烏衝突對結直腸癌藥物市場的影響突出了全球醫藥供應鏈的潛在脆弱性。它強調了藥品供應來源多樣化和發展當地製藥業的重要性，以加強自給自足，減少對進口藥品的依賴。

Market Overview

The Global Colorectal Cancer Drugs Market reached US$ 13.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 18.1 billion by 2030. The Global Colorectal Cancer Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2023-2030.

Colorectal cancer drugs encompass a range of therapeutic options for treating colorectal cancer, which affects the colon or rectum. These drugs inhibit tumor growth, prevent cancer cells from spreading, and improve patient outcomes. The major drug classes and specific medications used to treat colorectal cancer include chemotherapy, immunotherapy, and other combination drugs.

Furthermore, the identification of specific genetic mutations and molecular pathways implicated in colorectal cancer has led to the development of targeted therapies; researchers are exploring the benefits of combining different drugs to enhance treatment outcomes and the conduct of clinical trials allows for the evaluation of new medicines and treatment regimens are the factors expected to drive the colorectal cancer drugs over the forecast period.

Market Dynamics

The increasing clinical trial for colorectal cancer drugs is boosting the growth of the Global Colorectal Cancer Drug Market during the forecast period.

In September 2022, Pfizer, in collaboration with Merck KGaA, ONO Pharmaceutical, and Pierre Fabre, sponsored the BEACON CRC study. The study evaluated the effectiveness of encorafenib + cetuximab ± binimetinib regimens compared to standard of care in patients with previously treated metastatic colorectal cancer (mCRC) with a specific genetic mutation called BRAF V600E.

The randomized phase III BEACON study (NCT02928224) demonstrated that the encorafenib + cetuximab ± binimetinib regimens improved overall survival and objective response rate compared to the control group. This finding provided evidence for the efficacy of this combination therapy in treating BRAF V600E-mutant mCRC.

The ctDNA analysis demonstrated that reactivation of the MAPK pathway is a common resistance mechanism after inhibiting BRAF and EGFR, with or without MEK inhibition. Acquired mutations in the RAS-MEK signaling pathway were more frequently observed in patients treated with the doublet regimen (encorafenib + cetuximab), while enhanced receptor signaling was more prevalent in those receiving the triplet regimen (encorafenib + cetuximab + binimetinib).

The high costs of drugs for colorectal cancer are hampering the growth of the Global Colorectal Cancer Drugs Market in the forecast period.

According to the Centers for Disease Control and Prevention, the treatment expenses for colorectal cancer rank second highest among all types of cancer, comprising 12.6% of the total costs associated with cancer treatment.

Medical services accounted for $23.7 billion, while prescription drugs contributed $0.6 billion to these expenses. Furthermore, in terms of oral prescription drugs, the average costs per patient were found to be the greatest during the final year of life ($1,400), followed by the initial care phase ($400), and the continuing care phase (approximately $200). Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The colorectal cancer drugs market has experienced significant disruptions due to the COVID-19 pandemic. Healthcare systems globally have been impacted, leading to delays in cancer screenings, diagnosis, and treatments. Clinical trials for colorectal cancer drugs were also affected, with many being postponed, delayed, or modified to ensure patient safety and comply with pandemic-related restrictions.

Consequently, the development and introduction of new drugs have been slowed down. Additionally, the economic impact of the pandemic has created financial constraints for healthcare systems and individuals, potentially influencing the affordability and accessibility of colorectal cancer drugs. These combined factors have notably impacted the dynamics of the colorectal cancer drugs market.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has significantly impacted the availability of colorectal cancer drugs in Ukraine. Before the conflict, Ukraine relied heavily on Russia to import pharmaceuticals, including cancer drugs. However, following the conflict and subsequent trade restrictions, access to these drugs became limited, leading to a shortage of critical medications, including those used to treat colorectal cancer.

As a result of this shortage, patients have been unable to access essential drugs, leading to treatment delays and the use of alternative, less effective drugs. Additionally, the cost of imported drugs increased, making them less affordable for patients and healthcare systems. The situation was further compounded by the devaluation of the Ukrainian currency, making purchasing drugs from other countries more challenging.

The impact of the Russia-Ukraine conflict on the colorectal cancer drugs market highlights the potential vulnerabilities of global pharmaceutical supply chains. It underscores the importance of diversifying the sources of drug supplies and developing local pharmaceutical industries to enhance self-sufficiency and reduce dependence on imported drugs.

Segment Analysis

The Global Colorectal Cancer Drugs Market is segmented based on type, therapy, end user, distribution channel, and region.

The vascular endothelial growth factor (VEGF) inhibitors segment is expected to dominate the market over the forecast period.

The vascular endothelial growth factor (VEGF) inhibitors segment accounted for the highest market stake, accounting for approximately 1/3rd of the colorectal cancer drugs market in 2022. Vascular endothelial growth factor (VEGF) inhibitors have several advantages in the treatment of colorectal cancer. It works by blocking the activity of VEGF, a protein that promotes the formation of new blood vessels (angiogenesis).

For instance, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second-line chemotherapy.

Additionally, VEGF inhibitors are often used in combination with chemotherapy in the treatment of colorectal cancer. Studies have shown that adding VEGF inhibitors to chemotherapy regimens improves treatment response rates and overall survival compared to chemotherapy alone. This combination therapy approach can lead to more effective tumor control and increased patient outcomes.

Geographical Analysis

The increasing acquisitions by the market players, the growing prevalence of colorectal cancer, and rising product launches by the market players dominate the North American region.

North America is expected to dominate the catheter stabilization devices market, accounting for around 1/3rd of this market, with the U.S. being the major contributor.

According to the recent Colorectal Cancer Statistics 2023 report by the American Cancer Society (ACS), there has been a notable shift in colorectal cancer trends in the United States. The report reveals that the proportion of individuals diagnosed with advanced-stage colorectal cancer (CRC) has increased from 52% in the mid-2000s to 60% in 2019.

Moreover, the diagnoses of individuals under the age of 55 have doubled from 11% in 1995 to 20% in 2019, indicating a concerning rise in colorectal cancer among younger age groups. Overall, the report estimates that in 2023, approximately 153,020 people in the United States will receive a diagnosis of colorectal cancer, and 52,550 individuals will succumb to the disease. These figures highlight the significant impact and continued threat posed by colorectal cancer.

Furthermore, on March 13, 2023, Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

Hence , the North American region is expected to hold the largest market share over the forecast period due to the above factors.

Competitive Landscape

The major global players in the market include: Genentech, Inc., Eli Lilly, and Company, Pfizer, Abbott Laboratories, Sanofi S.A., Bristol-Myers Squibb, Amgen, Bristol-Myers Squib, Merck & Co., Inc., Teva Pharmaceuticals, Novartis, GlaxoSmithKline, Onyx among others.

Why Purchase the Report?

To visualize the Global Colorectal Cancer Drugs Market segmentation based on the type, therapy, end user, distribution channel, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of colorectal cancer drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Colorectal Cancer Drugs Market Report Would Provide Approximately 69 Tables, 72 Figures And 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Therapy
3.3. Snippet by End User
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The increasing clinical trial for colorectal cancer drugs
- 4.1.2. Restraints
  - 4.1.2.1. The high costs of drugs for colorectal cancer
- 4.1.3. Opportunity
  - 4.1.3.1. Growing focus on developing targeted therapies that specifically address the molecular characteristics
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
8.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
8.4. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
8.5. BRAF Or MEK Inhibitors
8.6. Tyrosine Kinase (TKI) Inhibitors
8.7. Immunomodulators
8.8. Others

9. By Therapy

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 9.1.2. Market Attractiveness Index, By Therapy
9.2. Immunotherapy*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Targeted therapy
9.4. Chemotherapy
9.5. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospital*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Research Institute
10.5. Others

11. By Distribution Channel

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.7.1. The U.S.
  - 12.2.7.2. Canada
  - 12.2.7.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.7.1. Germany
  - 12.3.7.2. The U.K.
  - 12.3.7.3. France
  - 12.3.7.4. Italy
  - 12.3.7.5. Spain
  - 12.3.7.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.7.1. Brazil
  - 12.4.7.2. Argentina
  - 12.4.7.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.7.1. China
  - 12.5.7.2. India
  - 12.5.7.3. Japan
  - 12.5.7.4. Australia
  - 12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Genentech, Inc.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Eli Lilly and Company
14.3. Pfizer
14.4. Sanofi S.A.
14.5. Bristol-Myers Squibb
14.6. Amgen
14.7. Merck & Co., Inc.
14.8. Teva Pharmaceuticals
14.9. Novartis
14.10. GlaxoSmithKline

LIST NOT EXHAUSTIVE